Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C5H9NO3 |
| Molecular Weight | 131.1299 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1CN[C@@H](C1)C(O)=O
InChI
InChIKey=PMMYEEVYMWASQN-DMTCNVIQSA-N
InChI=1S/C5H9NO3/c7-3-1-4(5(8)9)6-2-3/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4+/m1/s1
| Molecular Formula | C5H9NO3 |
| Molecular Weight | 131.1299 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
HYDROXYPROLINE, a hydroxylated form of the imino acid proline, is a major component of the protein collagen. For this reason, HYDROXYPROLINE content in biological fluids is used as a parameter of collagen catabolism, especially bone resorption or tissue degradation. A deficiency in ascorbic acid can result in impaired HYDROXYPROLINE formation.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Prolidase-dependent regulation of TGF β (corrected) and TGF β receptor expressions in human skin fibroblasts. | 2010-12-15 |
|
| Immunostimulatory activities of Bacillus simplex DR-834 to carp (Cyprinus carpio). | 2010-09 |
|
| The aberrance of the 4S diastereomer of 4-hydroxyproline. | 2010-08-11 |
|
| Essential modification of the Sircol Collagen Assay for the accurate quantification of collagen content in complex protein solutions. | 2010-08 |
|
| Thermodynamic consequences of incorporating 4-substituted proline derivatives into a small helical protein. | 2010-05-18 |
|
| Prolyl 4-hydroxylase. | 2010-04 |
|
| Quantum mechanical and NMR studies of ring puckering and cis/trans-rotameric interconversion in prolines and hydroxyprolines. | 2009-10-08 |
|
| Origin of the stability conferred upon collagen by fluorination. | 2009-07-15 |
|
| Stereoselective synthesis and biological evaluations of novel 3'-deoxy-4'-azaribonucleosides as inhibitors of hepatitis C virus RNA replication. | 2009-07-09 |
|
| Direct and continuous assay for prolyl 4-hydroxylase. | 2009-03-15 |
|
| Bone phenotypes in response to gonadotropin misexpression: the role for gonadotropins in postmenopausal osteoporosis. | 2008-11-30 |
|
| Conformational preferences of substrates for human prolyl 4-hydroxylase. | 2008-09-09 |
|
| 4-chloroprolines: synthesis, conformational analysis, and effect on the collagen triple helix. | 2008-05 |
|
| Extracellular matrix and HIF-1 signaling: the role of prolidase. | 2008-03-15 |
|
| Comparison of plasma malondialdehyde, glutathione, glutathione peroxidase, hydroxyproline and selenium levels in patients with vitiligo and healthy controls. | 2008 |
|
| Effects of glycosylation of (2S,4R)-4-hydroxyproline on the conformation, kinetics, and thermodynamics of prolyl amide isomerization. | 2007-09-26 |
|
| Nutraceuticals in the management of osteoarthritis. | 2007-08 |
|
| p53 activation by knockdown technologies. | 2007-05-25 |
|
| Oxaceprol--a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug. | 2007-04-10 |
|
| Effects of dietary conjugated linoleic acid on production and metabolic parameters in transition dairy cows grazing fresh pasture. | 2006-08 |
|
| 2005 Emil Thomas Kaiser Award. | 2006-05 |
|
| Dual mechanism of zinc-proline catalyzed aldol reactions in water. | 2006-04-14 |
|
| Conformational preference and cis-trans isomerization of 4(R)-substituted proline residues. | 2006-02-02 |
|
| Stereoelectronic effects on polyproline conformation. | 2006-01 |
|
| Stereoelectronic and steric effects in the collagen triple helix: toward a code for strand association. | 2005-11-16 |
|
| Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. | 2005-10 |
|
| Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability. | 2005-07 |
|
| The crystal structure of the collagen-like polypeptide (glycyl-4(R)-hydroxyprolyl-4(R)-hydroxyprolyl)9 at 1.55 A resolution shows up-puckering of the proline ring in the Xaa position. | 2005-05-27 |
|
| Adenosine postsynaptically modulates supraoptic neuronal excitability. | 2005-01 |
|
| O-acylation of hydroxyproline residues: effect on peptide-bond isomerization and collagen stability. | 2005 |
|
| Substituted 2-azabicyclo[2.1.1]hexanes as constrained proline analogues: implications for collagen stability. | 2004-12-10 |
|
| Prescription of drugs to pregnant women in France: the HIMAGE study. | 2004-04-03 |
|
| Transport of pharmacologically active proline derivatives by the human proton-coupled amino acid transporter hPAT1. | 2004-04 |
|
| Evolutionary and functional implications of the complex glycosylation of Skp1, a cytoplasmic/nuclear glycoprotein associated with polyubiquitination. | 2003-02 |
|
| In vivo imaging approaches in animal models of rheumatoid arthritis. | 2003 |
|
| [Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis]. | 2002-11 |
|
| Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. | 2002-09 |
|
| Biochemical measurements in the prediction of histologic subtype of renal transplant bone disease in women. | 2002-08 |
|
| Oxaceprol, an atypical inhibitor of inflammation, reduces leukocyte adherence in mouse antigen-induced arthritis. | 2001-06 |
|
| Measurement of histidinohydroxylysinonorleucine and hydroxyproline in skin collagen by reversed-phase high-performance liquid chromatography after 9-fluorenylmethyl chloroformate labeling. | 1997-10-15 |
|
| Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. | 1997-07 |
|
| Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis. | 1996-07 |
|
| Hydroxyproline and total protein levels in gingiva from patients treated with phenytoin and cyclosporine-A. | 1996-03 |
|
| Hydroxyproline and total protein levels in gingiva and gingival crevicular fluid in patients with juvenile, rapidly progressive, and adult periodontitis. | 1993-05 |
|
| Hydroxyproline and total protein levels in gingiva and gingival crevicular fluid in periodontally healthy human subjects. | 1992-09 |
|
| Quantitation of hydroxyproline isomers in acid hydrolysates by high-performance liquid chromatography. | 1984-05-01 |
|
| A criterion to determine whether cis-4-hydroxyproline is produced in animal tissues. | 1984-03 |
|
| Separation and evaluation of the cis and trans isomers of hydroxyprolines: effect of hydrolysis on the epimerization. | 1984-02 |
|
| Urinary excretion of hydroxyproline, hydroxylysine and hydroxylysine glycosides by patients with Paget's disease of bone and carcinoma with metastases in bone. | 1979-03-15 |
|
| Studies on bound trans-4-hydroxy-L-proline in sandal (Santalum album L.). | 1970-10 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:13 GMT 2025
by
admin
on
Mon Mar 31 17:49:13 GMT 2025
|
| Record UNII |
RMB44WO89X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
27181-7
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
2451-3
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
13374-4
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
56939-2
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
59392-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
NCI_THESAURUS |
C29596
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
53153-3
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
2445-5
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
13763-8
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
CFR |
21 CFR 862.1400
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
15135-7
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
20647-4
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
17001-9
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
47651-5
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
2447-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
53154-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
26810-2
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
28601-3
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
13996-4
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
53393-5
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
11049-4
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
44386-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
DSLD |
1137 (Number of products:1)
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
26740-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
53397-6
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
6710-8
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
2446-3
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
14785-0
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
25110-8
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
DSLD |
1769 (Number of products:28)
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
59383-0
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
12720-9
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
53152-5
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
32250-3
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
25935-8
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
13401-5
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
26596-7
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
25934-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
15143-1
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
||
|
LOINC |
32249-5
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB08847
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
1311548
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | RxNorm | ||
|
6912-67-0
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
18095
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
18240
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
Hydroxyproline
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
DTXSID10883225
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
46704
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
4272
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
51-35-4
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
100000151964
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
20392
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
SUB126409
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
D006909
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
m6148
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
C76144
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
200-091-9
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
RMB44WO89X
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
58419
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
RMB44WO89X
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
5810
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY | |||
|
SUB129244
Created by
admin on Mon Mar 31 17:49:14 GMT 2025 , Edited by admin on Mon Mar 31 17:49:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|